aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings. It is also developing ATYR1940, a therapeutic candidate based on a protein naturally secreted from muscle for the treatment of facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy, and duchenne muscular dystrophy. aTyr Pharma, Inc. was founded in 2005 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNASDAQ:LIFE
CUSIP53217V10
Phone858-731-8389
Debt
Debt-to-Equity Ratio0.26
Current Ratio5.96
Quick Ratio5.96
Price-To-Earnings
Trailing P/E Ratio-0.37
Forward P/E Ratio-0.53
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.16 per share
Price / Book0.32
Profitability
EPS (Most Recent Fiscal Year)($1.87)
Net Income$-48,200,000.00
Net MarginsN/A
Return on Equity-74.02%
Return on Assets-52.93%
Miscellaneous
Employees65
Outstanding Shares29,860,000
Market Cap$19.44 million
aTyr Pharma (NASDAQ:LIFE) Frequently Asked Questions
What is aTyr Pharma's stock symbol?
aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."
How were aTyr Pharma's earnings last quarter?
aTyr Pharma Inc (NASDAQ:LIFE) announced its quarterly earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.35) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.34) by $0.01. View aTyr Pharma's Earnings History.
When is aTyr Pharma's next earnings date?
What price target have analysts set for LIFE?
4 Wall Street analysts have issued 12 month price objectives for aTyr Pharma's shares. Their forecasts range from $0.75 to $3.00. On average, they expect aTyr Pharma's stock price to reach $1.5833 in the next twelve months. This suggests a possible upside of 129.5% from the stock's current price. View Analyst Price Targets for aTyr Pharma.
What is the consensus analysts' recommendation for aTyr Pharma?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for aTyr Pharma.
Are investors shorting aTyr Pharma?
aTyr Pharma saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 1,599,680 shares, an increase of 37.8% from the July 13th total of 1,160,737 shares. Based on an average daily volume of 563,016 shares, the short-interest ratio is currently 2.8 days. Currently, 8.4% of the company's shares are short sold. View aTyr Pharma's Current Options Chain.
Who are some of aTyr Pharma's key competitors?
Some companies that are related to aTyr Pharma include Applied Genetic Technologies (AGTC), Aevi Genomic Medicine (GNMX), TRACON Pharmaceuticals (TCON), Entera Bio (ENTX), Oncobiologics (ONS), Genocea Biosciences (GNCA), BioCardia (BCDA), Curis (CRIS), Proteon Therapeutics (PRTO), BIONDVAX PHARMA/S (BVXV), CytRx (CYTR), Vical (VICL), Arsanis (ASNS), Microbot Medical (MBOT) and Vaxart (VXRT).
Who are aTyr Pharma's key executives?
aTyr Pharma's management team includes the folowing people:
- Dr. Sanjay S. Shukla, Pres, CEO & Director (Age 46)
- Dr. Paul R. Schimmel, Founder & Director (Age 77)
- Dr. David J. King, Chief Scientific Officer (Age 59)
- Dr. John D. Mendlein, Strategic Advisor & Director (Age 58)
- Dr. Sanuj K. Ravindran, Bus. Advisor (Age 46)
When did aTyr Pharma IPO?
(LIFE) raised $76 million in an IPO on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.
Has aTyr Pharma been receiving favorable news coverage?
Media headlines about LIFE stock have been trending somewhat positive this week, Accern reports. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. aTyr Pharma earned a media and rumor sentiment score of 0.14 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 46.01 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for aTyr Pharma.
Who are aTyr Pharma's major shareholders?
aTyr Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.79%) and BlackRock Inc. (1.04%). Company insiders that own aTyr Pharma stock include Ashraf Amanullah, Ecor1 Capital Fund Qualified,, John Mendlein and Paul Schimmel. View Institutional Ownership Trends for aTyr Pharma.
Which major investors are selling aTyr Pharma stock?
LIFE stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc.. Company insiders that have sold aTyr Pharma company stock in the last year include Ashraf Amanullah and Ecor1 Capital Fund Qualified,. View Insider Buying and Selling for aTyr Pharma.
Which major investors are buying aTyr Pharma stock?
LIFE stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought aTyr Pharma stock in the last two years include Ashraf Amanullah, John Mendlein and Paul Schimmel. View Insider Buying and Selling for aTyr Pharma.
How do I buy shares of aTyr Pharma?
Shares of LIFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is aTyr Pharma's stock price today?
One share of LIFE stock can currently be purchased for approximately $0.69.
How big of a company is aTyr Pharma?
aTyr Pharma has a market capitalization of $19.44 million. The biotechnology company earns $-48,200,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis. aTyr Pharma employs 65 workers across the globe.
How can I contact aTyr Pharma?
aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-731-8389 or via email at [email protected]
MarketBeat Community Rating for aTyr Pharma (NASDAQ LIFE)
MarketBeat's community ratings are surveys of what our community members think about aTyr Pharma and other stocks. Vote "Outperform" if you believe LIFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LIFE will underperform the S&P 500 over the long term. You may vote once every thirty days.
